Vaderis Therapeutics AG announces Initiation of Clinical PoC trial in HHT

Vaderis Therapeutics AG (Vaderis), one of the clinical stage biotechnology company focused on developing treatments for rare diseases associated with vascular malformations, recently announced its emergence from stealth and initiation of its INSIGHT proof-of-concept (PoC) clinical trial in patients suffering from Hereditary Haemorrhagic Telangiectasia (HHT), also known as Osler-Weber-Rendu Syndrome. Vaderis was established in 2019 […]